Share Price, page-9969

I'd argue the first thing has already occurred, and extreme negativity around Daybue is already mostly priced in. The official company statements since the Q4 results don't hint at a larger problem, so short of them pulling their previous guidance I don't see how that will impact us more than it has already has.

The Pit Hopkins results are out of our control and that's the nature of these trials. The market has forgotten about our outstanding PMS results, and the 2 other trials seemingly. Our results being negative would clearly be bad for our SP, no doubt. Our results being strong, but not as strong as PMS is also a good result given, we know the P2 results for Trof (which led ultimately to an NDA) had far weaker efficacy data at this stage. I think it is far too early to judge the commercial success of Daybue before it has been on sale for a single full year, within a single market.